VERIGRAFT is pioneering advancements in personalized tissue transplantation, focusing on creating custom-made tissues that closely resemble a patient's own biological material. This innovative approach aims to significantly reduce the risk of rejection by the immune system, which is a common challenge in traditional transplantation methods. By addressing the issue of tissue rejection, VERIGRAFT seeks to eliminate the need for lifelong immunosuppressant medications, which can lead to serious side effects such as increased susceptibility to infections and cancer. This technology represents a potential breakthrough for patients requiring organ or tissue transplants, particularly in life-threatening situations.

The company's research and development efforts are centered on creating therapies that enhance the compatibility of transplanted tissues with the recipient's body. By utilizing advanced techniques to modify donated tissues, VERIGRAFT aims to improve patient outcomes and expand the possibilities for transplantation. Their commitment to innovation in personalized medicine positions them at the forefront of addressing previously incurable diseases, making significant strides in the field of regenerative medicine and transplantation.

Sweden

VERIGRAFT generates personalized tissue-engineered transplants for use in regenerative medicine. The company's unique technology platform turns donated allogeneic ("foreign") tissue into an autologous-like ("personalized") tissue and thus avoids transplant rejection and the need for life-long immunosuppression. Donated, allogenic tissue is patient-individualized by a combination of DC (Decellularization) and RC (Reconditioning/Recellularization) processes. VERIGRAFT's development pipeline comprises products in the areas of vascular regeneration as well as peripheral nerve repair.

VERIGRAFT

Company Details